Dako Augments Diagnostic/Drug Tandem Strategy Post-Merger
This article was originally published in The Gray Sheet
Executive Summary
DakoCytomation will develop an epidermal growth factor (EGF) receptor diagnostic kit to work in tandem with a cancer drug that blocks EGF receptors